Valuation: Exelixis, Inc.

Market Cap 14.35B 12.58B 11.62B 10.74B 20.35B 1,374B 20.76B 140B 54.27B 672B 53.88B 52.7B 2,334B P/E 2026 *
18x
P/E 2027 * 15.3x
Enterprise Value 13.57B 11.91B 10.99B 10.16B 19.25B 1,300B 19.64B 132B 51.34B 636B 50.97B 49.86B 2,208B EV / Sales 2026 *
5.22x
EV / Sales 2027 * 4.31x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 day+2.87%
1 week+4.45%
Current month+4.45%
1 week 44.53
Extreme 44.532
46.17
1 month 41.29
Extreme 41.288
46.17
Current year 41.29
Extreme 41.288
46.17
1 year 41.29
Extreme 41.288
46.17
3 years 41.29
Extreme 41.288
46.17
5 years 41.29
Extreme 41.288
46.17
10 years 41.29
Extreme 41.288
46.17
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+2.87%+4.45% - - 14.35B
-1.53%+0.78%+72.33%+127.47% 57.72B
-2.45%-7.32%+65.23%+83.15% 52.65B
+3.25%+8.55%+20.81%+469.36% 24.46B
-1.44%-1.45%-17.11%-13.84% 23.84B
-3.05%+3.06%+42.36%-5.66% 19.28B
-0.24%+5.11%+38.76%-25.95% 17.8B
+2.34%+14.18%+220.96%+380.99% 17.29B
-6.73%+9.90%+36.04% - 15.28B
-0.66%+8.87%-31.91%+628.14% 12.33B
Average -0.78%+5.65%+49.72%+205.46% 26.74B
Weighted average by Cap. -1.04%+2.90%+54.83%+162.59%

Financials

2026 *2027 *
Net sales 2.6B 2.28B 2.11B 1.95B 3.69B 249B 3.76B 25.31B 9.83B 122B 9.76B 9.55B 423B 2.93B 2.57B 2.37B 2.19B 4.16B 281B 4.24B 28.54B 11.09B 137B 11.01B 10.77B 477B
Net income 819M 718M 663M 613M 1.16B 78.39B 1.18B 7.97B 3.1B 38.36B 3.07B 3.01B 133B 946M 830M 766M 708M 1.34B 90.57B 1.37B 9.21B 3.58B 44.32B 3.55B 3.47B 154B
Net Debt -774M -679M -627M -579M -1.1B -74.09B -1.12B -7.53B -2.93B -36.25B -2.91B -2.84B -126B -1.72B -1.51B -1.39B -1.28B -2.43B -164B -2.48B -16.71B -6.49B -80.41B -6.44B -6.3B -279B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change
26-07-07 CHF 46.17 +2.87%
26-07-06 CHF 44.88 +0.78%
26-07-03 CHF 44.53 -0.13%
26-07-02 CHF 44.59 +2.80%
26-07-01 CHF 43.38 -1.87%
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
57.08USD
Average target price
50.38USD
Spread / Average Target
-11.75%

Quarterly revenue - Rate of surprise